Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 6/20 | 0.44 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13236361 | 0.89 | POLB (0.59) | KMT2APOLBHDAC1HDAC6NOD1 | |
| SCHEMBL13236359 | 0.86 | KMT2A (0.50) | KMT2APOLB | |
| SCHEMBL7761870 | 0.85 | KMT2A (0.64) | KMT2APOLBNOD1 | |
| SCHEMBL7208303 | 0.85 | KMT2A (0.64) | KMT2APOLBNOD1 | |
| SCHEMBL28083227 | 0.85 | KMT2A (0.64) | KMT2APOLBNOD1 | |
| SCHEMBL28083226 | 0.85 | KMT2A (0.64) | KMT2APOLBNOD1 | |
| SCHEMBL13079813 | 0.84 | KMT2A (0.58) | KMT2APOLBHDAC1HDAC6NOD1 | |
| SCHEMBL28790681 | 0.81 | L3MBTL1 (0.54) | KMT2APOLB | |
| SCHEMBL28790680 | 0.81 | L3MBTL1 (0.54) | KMT2APOLB | |
| SCHEMBL16948612 | 0.80 | KMT2A (0.51) | KMT2APOLBNOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220396563-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. | 2022-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220396563-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | CFD, TFPI, CFH | KMT2A 4295/4885POLB 3304/4885HDAC1 1872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.